March a Thank our results press This Good our we Thank first XX, issued call. for everyone. morning, joining reporting for XXXX. Brendan. you, quarter ended you release morning,
on and cash progress with move as pleased closer flow to our generating profitability sustained we We basis. continued free a are
million, the significant XXXX. from sequential fourth improvement a million $X achieved QX of of quarter for we of financial the $X.X Some revenue included, during highlights
XX.X% of best margin gross quarters. XX represents in the gross last our QX Our margin
and channel product channel market increased position we our important our in maintain retail to the share #X continue in well. have We sales natural this also as
our a acquisition strategy. and just a on continue in Colorado-based M&A And release, we our execute manufacturer. disclosed yesterday, We tincture to of Elevated softgel Softgels, press
a strategy. Before comments execution our continue, few and on M&A of implementation I the
communicated last and we M&A we opportunities. have numerous As the of reviewed couple for actively years, outbound have inbound
exchange. We is including with revenue are our same for a to that to looking for increase Sciences important distribution. and and profitably on investors our profitably.
The achieve cost opportunities have to people greater process scale our our be leverage to know and increased list scale major greater and it assets, We stock brands, CV is true an must We opportunity to efficiency have can transactions profitable.
We are making progress.
strategic profitably. X last we now transactions increasing that revenue are to completed M&A components months, both and the have scale Over X
the in preparing made in launch we During Foods progress market. QX, products Cultured U.S. for
We the market. on and packaging, have worked branding, U.S. messaging product formulation for
launch expect phase sometime first We of the this during year. to QX of products
We markets. are expanding EU team sales non-U.S. the our and other in also in EU supporting
production sales Softgels market facility. clients to registered opportunity to This FDA acquisition runs, our the Our with development for GMP-certified a use low minimum and quantity allowing provides new customers. further and to Elevated. new Elevated of Softgels of is product increase creates current for to and large allowing transaction flexibility, speed most ability us to recent efficient order Elevated capital of operational of increase
intend products, creating efficiency. also production cost for our of significant of key certain in-source potential We to
Now moving on.
to to we are the operational During in with during planning QX other new our efficiency achieved launch result QX, efforts in balance numerous objectives, development products will company other to numerous product non-CBD savings throughout as we the SG&A. a overall anticipate +PlusCBD areas, flagship new cost organic several that efficiency contribute including as growth including: structure we of well cash lower our our continue continued brand as XXXX efforts cost And products. gains and of also
QX, of again, margin a gross continuous XX.X% the cost-efficient in margin to improved in our company. Our demonstrates last best improvement operating in our XX commitment quarters,
On list through organic top company product channel, strategy. to brands. X% to top improve. #X switching to our the in selling the merchandising product the the to continue the scale invest the retail our goal growth. are slow-moving the retail retailers M&A increase and as same is of marketing us retail contraction We and our side, take the to continuously know brand revenue help through of see we market are trust of to channels in the concentration growth and optimize investment. in BXB our are to market Customers X remove and In share Brand continues natural BXC they share BXC in brands at or advertising, changing natural channel.
The we brands and continues and channel continue
orders are grow critical value. and average will our education contraction, new order visitors, BXC channel. consumer subscription brand seeing brand in the further that We and We and trust including in results help good all believe company increased increased strong BXC all our KPIs,
function but like ingredient market We be Consumers evolves.
Product claim as will category products, product a each generate growth brands the to development as are to products structure revenues total sales prepared can demanding that continue of grow be new quarter. important carry our significant strategy our channel a share and increasingly are take they for trusted. that multi-active +PlusCBD portion want high-quality the
this topical under launches address products proactively during products several our to including have calm XXXX and to our planned complement trend relief wellness product line, sleep, and our over-the-counter continue line. We and
claims are new launch specific and sleep and states, strong pain customers their anxiety, product innovate for win responsive will that disorders. and of new to We science customers. supports and believe to trust and our continue products our including need our and existing that the will We loyalty
On continues lot regulatory matters, a be there activity. of to
to be at possible quality can cannabis to products on seen III actively the helps continue hemp the a we optimistic FDA involved cannabis an remain Congress be our to is way. progress grow Schedule further trusted legislative a have progress to level including in frustrating, advance in Inaction and and framework, by pushing We environment progress rescheduling and state but regarding industry Congress and companies responsible make Incremental of the creates industry and status. regulatory with progress.
development formulations of containing program. program partners this see believe and nicotine. to covers by this of technology, even drug believe use administering addiction an patent smokeless on significant development tobacco we treating protected This positive of internally, We continues is pharmaceutical treatment program asset. countries, which this in our we has collaboration element tobacco to smokeless in be XX and have continue drug undervalued though And value. CBD We program addiction methods
we challenges, to Our but ourselves the industry in has positioning compete are current environment.
to this streamlining including and align numerous doing in our are the by increasing company profitability. operations, and growth for We cost ways, efficiency our
in We our progress strengths, great trust products, company's the a the our our our brand have in strength lean, structuring cost-efficient made leverage of distribution. employees, that and to organization positioned our is
Our strong operating strategy provide that platform utilize has operational scale acquire revenue, M&A to efficiency. our allowed increase and an to add us assets
promote Our to Foods will acquisitions Cultured add last move just toward over Elevated line the profitability. top and we X quarters, revenue recently efficiency as cost and XXXX in the including Softgels, December
revenues cost outbound and M&A increasing to opportunities of that strategic efficiency. will continue evaluate We and support plan our inbound
towards is make and and that immediate Our to profitability achieve cash positive, goal. flow we goal progress continue to
to turn pause will now and the Joerg. over me call Let I
